Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Publikováno v:
Targeted Oncology. 17:597-604
Small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, are treatment options for metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumors have a mutation that leads to MET
Autor:
Yasushi Okuno, Junichi Shimizu, Katsutoshi Seto, Shiro Fujita, Ryohei Katayama, Waki Hosoda, Yoshitsugu Horio, Toyoaki Hida, Mitsugu Araki, Katsuhiro Masago, Hiromi Furuta, Eiichi Sasaki, Yukari Sagae
Publikováno v:
Journal of Thoracic Oncology. 16:477-482
Objectives The purposes of this study are to clarify the details of the ALK tyrosine kinase inhibitor (TKI) resistance mechanism in rebiopsy cases and to predict novel resistance gene alterations using molecular dynamics simulation. Methods A total o
Autor:
Nobuyuki Yamamoto, Koichi Goto, Yuichiro Ohe, Tatsuya Yoshida, Makoto Nishio, Toru Kumagai, Toyoaki Hida, Kentarou Kudou, Pingkuan Zhang, Kazuhiko Nakagawa, Ryo Toyozawa, Takayuki Asato, Tadasuke Shimokawaji, Takashi Seto
Publikováno v:
Journal of Thoracic Oncology. 16:452-463
Introduction This phase 2 trial evaluated the efficacy and safety of brigatinib in patients with advanced ALK-positive NSCLC refractory to alectinib or other ALK tyrosine kinase inhibitors (TKIs). Methods This single-arm, multicenter, open-label stud
Autor:
Mie Suzuki, Hidetoshi Hayashi, Makoto Nishio, Gerson Peltz, Takashi Nagasawa, Toyoaki Hida, Takashi Seto, Kei Fukuhara, Masayuki Ohkura, Miyako Satouchi, Yasushi Goto, Holger Thurm, Masahiro Morise, Naoyuki Nogami, Toshiaki Takahashi, Seiji Niho, Jun Sakakibara-Konishi
Publikováno v:
Cancer Science
Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multina
Autor:
Geoffrey I. Shapiro, Liza C. Villaruz, Jeffrey W. Clark, Alexander Drilon, Gregory J. Riely, Danielle Murphy, Tiziana Usari, D. Ross Camidge, Miyako Satouchi, Paul K. Paik, Sherry Li, Mark M. Awad, Toyoaki Hida, Jared Weiss, Rebecca S. Heist, Hidetoshi Hayashi, Sherry C. Wang, Benjamin Solomon, Sai-Hong Ignatius Ou, Keith D. Wilner, Gregory A. Otterson
Publikováno v:
Nature medicine
MET exon 14 alterations are oncogenic drivers of non-small cell lung cancers (NSCLCs).1 These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition.2 Crizotinib is a multikinase inhibitor with potent act
Autor:
Yoshinori Hasegawa, Yasushi Yatabe, Hiromichi Ebi, Yoshitsugu Horio, Yuko Hayashi, Toyoaki Hida, Chiaki Kondoh
Publikováno v:
Histopathology. 75:20-28
Aims Anaplastic lymphoma kinase (ALK) immunohistochemistry has shifted from being a screening tool to being a sole determinant for ALK-targeted therapy. Recent articles have referred to small-cell lung cancer (SCLC) transformation as a resistance mec
Autor:
Testuya Mitsudomi, Shingo Matsumoto, Hidehito Horinouchi, Fumihiko Hirai, Takashi Seto, Katsuyuki Hotta, Kota Tokushige, Masataka Yonemura, Masayuki Ito, Young Hak Kim, Koichi Ayukawa, Makoto Nishio, Toyoaki Hida, Makoto Maemondo, Masayuki Takeda
Publikováno v:
Cancer Science
Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase (ALK)-rearranged metastat
Autor:
Miyako Satouchi, Katsuyuki Hotta, Young Hak Kim, Satoshi Watanabe, Tetsuya Mitsudomi, Morihiko Hayashi, Makoto Nishio, Toshiyuki Kozuki, Hiroshi Nokihara, Toru Kumagai, Koichi Azuma, Takashi Asakawa, Toyoaki Hida, Nobuyuki Yamamoto, Koichi Goto, Masahiro Morise, Wakako Hasegawa, Yuichi Takiguchi, Tomohide Tamura, Takashi Seto, Kazuhiko Nakagawa, Ryo Koyama, Hiroshige Yoshioka
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
The J-ALEX study compared the efficacy and safety of alectinib with crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). Superiority in independent review facility (IRF)-assessed progression-free survival (PF
Autor:
Young Hak Kim, Makoto Nishio, Hiroshige Yoshioka, Hiroshi Nokihara, Miyako Satouchi, Kazuhiko Nakagawa, Toru Kumagai, Takashi Seto, Katsuyuki Hotta, Masahiro Morise, Toyoaki Hida, Satoshi Watanabe, Nobuyuki Yamamoto, Tetsuya Mitsudomi, Takuya Yoshimoto, Koichi Azuma, Tomohide Tamura, Koichi Goto, Yuichi Takiguchi, Toshiyuki Kozuki
Publikováno v:
Journal of Clinical Oncology. 39:9022-9022
9022 Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Japanese patients randomized to the ALC, compared with those assigned in the